pending deals who fell today on the proposal included Shire (NASDAQ: SHPG ), AbbVie (NYSE: ABBV ), Auxilium Pharma (NASDAQ: AUXL ) and QLT (NASDAQ: QLTI ). In an unprecedented move for a U.S. retailer, Walgreen (NYSE: WAG ) also is weighing leaving
June 26 (Reuters) - Auxilium Pharmaceuticals Inc will buy Canadian eye drug maker QLT Inc for $346 million in the latest pharma deal aimed at cutting tax bills.
of Dupuytren's contracture in adult patients with a palpable cord. BioSpecifics' development partner Auxilium Pharmaceuticals ( AUXL ) partnered with SOBI in 2013 for the marketing of XIAPEX in 71 Eurasian and African countries. XIAPEX
Gainers: UNXL +23% . IRM +18% . ROYL +13% . AGEN +13% . AUXL +10% . DRWI +10% . NBR +10% . ONVO +10% . CJES +9% . NEON +8% . Losers: RDEN -12% . BBBY -8% . BCS -6% . Post your comment!
Auxilium Pharmaceuticals ( AUXL ) and Canadian biotech QLT Inc. enter ..... renamed "New Auxilium." Current AUXL shareholders will be receive 3.1359 QLT shares for each AUXL share. AUXL shareholders will own
We’re not surprised by QLT’s announcement that it will merge with Auxilium Pharmaceuticals . Following QLT’s recent direction of divesting assets and slashing operating costs, a takeover seemed inevitable. Auxilium seems
June 26 (Reuters) - Auxilium Pharmaceuticals Inc said it would buy Canadian eye drug maker QLT Inc in an all-stock deal to gain access to QLT's experimental treatment for retinal diseases caused by gene mutations.
(Reuters) - Auxilium Pharmaceuticals Inc reported a better-than-expected adjusted quarterly profit, boosted by strong drug sales from a recently acquired company, and narrowed its full-year revenue...
April 29 (Reuters) - Auxilium Pharmaceuticals Inc reported a big drop in quarterly sales in the United States for both of its drugs, and said it acquired Actient Holdings LLC to bolster its urology...
We are no longer providing equity research on Auxilium Pharmaceuticals AUXL . We provide broad coverage of more than 1,700 companies across more than 140 industries, and adjust our coverage as necessary based on client demand and investor interest.